Another recent, smaller, chart review focussed on 40 patients who switched from liraglutide to semaglutide
doi: 10.1038/s41572-022-00357-7 [DOI] [PubMed] [Google Scholar] 38
However, Novo Nordisk has recently developed monoclonal antibodies which, through targeting of the extracellular domain of GLP-1R, allow the detection of GLP-1R in human and rodent tissues with improved selectivity [[392], [393], [394]]
Information here is drawn from the published trial record, FDA regulatory documents, and animal studies
We explained that, if finalized, the proposed criteria to determine an ACO's eligibility to enter an agreement period, specified under new 425.600(h), would be applied in determining participation options for ACOs entering an agreement period beginning on or after January 1, 2027